top of page

Understanding molecular and phenotypic effects of cyclo-oxygenase inhibition in the zebrafish

Funder: BBSRC/Astrazeneca 

Millions of people worldwide use non-steroidal anti-inflammatory drugs (NSAIDs) to treat a wide variety of health conditions involving inflammation and pain In addition to their positive therapeutic effect, the use of NSAIDs, especially when long-term, is associated with an increased risk of adverse events in multiple organs/systems, including gastrointestinal and cardiovascular systems. These pharmaceuticals act by inhibiting one or both isoforms of the enzyme cyclo-oxygenase (COX), which catalyse the synthesis of prostaglandins, chemicals that promote inflammation, pain, and fever. Major advances have been made in our understanding of NSAIDs pharmacology and toxicology; however, many aspects of the biological significance of COX inhibition still remain poorly understood. In this project, we will use the zebrafish as the experimental model to study the effects of NSAIDs on immune and gastro-intestinal system and will explore the interplay between the two responses.


(2020) Pharmacology-informed prediction of the risk posed to fish by mixtures of non-steroidal anti-inflammatory drugs (NSAIDs) in the environment.

Marmon, P.; Owen, S.F.; Margiotta-Casaluci, L. Environment International 146, 106222. Link


bottom of page